NAS:CDXS (USA) Also trade in: Germany UK

Codexis Inc

$ 18.74 -0.52 (-2.7%)
Volume: 419,596 Avg Vol (1m): 341,663
Market Cap $: 1.08 Bil Enterprise Value $: 1.03 Bil
P/E (TTM): 0.00 P/B: 19.82
Earnings Power Value -2.17
Net Current Asset Value 0.25
Tangible Book 0.89
Projected FCF -1.19
Median P/S Value 3.59
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 7/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 195.55
Cash-To-Debt ranked higher than
53.34% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
CDXS: 195.55
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 2.71, Med: 10000, Max: 10000
Current: 195.55
2.71
10000
Equity-to-Asset 0.51
Equity-to-Asset ranked higher than
50.20% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
CDXS: 0.51
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -1.82, Med: 0.62, Max: 0.79
Current: 0.51
-1.82
0.79
Debt-to-Equity 0.01
Debt-to-Equity ranked lower than
100.00% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
CDXS: 0.01
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -0.2, Med: 0, Max: 0.05
Current: 0.01
-0.2
0.05
Debt-to-EBITDA -0.03
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
CDXS: -0.03
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -0.66, Med: -0.01, Max: -0.01
Current: -0.03
-0.66
-0.01
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 9.47
DISTRESS
GREY
SAFE
Beneish M-Score -1.30
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 8.67%

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -19.03
Operating Margin ranked higher than
61.24% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
CDXS: -19.03
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -128.9, Med: -20.4, Max: -6.65
Current: -19.03
-128.9
-6.65
Net Margin % -18.22
Net Margin ranked higher than
61.74% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
CDXS: -18.22
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -129.39, Med: -21.3, Max: -7.97
Current: -18.22
-129.39
-7.97
ROE % -24.62
ROE ranked lower than
59.56% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
CDXS: -24.62
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -105.38, Med: -37.42, Max: -15.76
Current: -24.62
-105.38
-15.76
ROA % -14.92
ROA ranked higher than
51.11% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
CDXS: -14.92
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -52.02, Med: -22.6, Max: -7.11
Current: -14.92
-52.02
-7.11
ROC (Joel Greenblatt) % -290.90
ROC (Joel Greenblatt) ranked lower than
51.54% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
CDXS: -290.9
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -924.35, Med: -258.51, Max: -35.45
Current: -290.9
-924.35
-35.45
3-Year Total Revenue Growth Rate 13.20
3-Year Revenue Growth Rate ranked higher than
56.99% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
CDXS: 3.1
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -57.7, Med: -23.15, Max: 92
Current: 3.1
-57.7
92
3-Year Total EBITDA Growth Rate -62.60
3-Year EBITDA Growth Rate ranked lower than
68.58% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
CDXS: -47.9
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
N/A
3-Year EPS w/o NRI Growth Rate -3.40
3-Year EPS w/o NRI Growth Rate ranked lower than
100.00% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
CDXS: -3.4
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -3.1, Max: 52.3
Current: -3.4
0
52.3

» CDXS's 30-Y Financials

Financials (Next Earnings Date: 2019-08-08)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:CDXS

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 541714    SIC : 8731
Compare XTER:BIO3 NAS:NGM HKSE:06826 NAS:SPPI XKRX:003000 NAS:CMTA NAS:CHRS SZSE:300255 NAS:EIDX NAS:RCKT TSE:4565 NAS:CLVS XPAR:GNFT SZSE:300204 XMAD:ROVI OSTO:RECI B NAS:GOSS NAS:FATE NAS:ALDR NAS:RARX
Traded in other countries 4QK.Germany 0I0X.UK
Address 200 Penobscot Drive, Redwood City, CA, USA, 94063
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins and developing biocatalyst products. The firm's products and services include Screening and Evolution services, Enzymes, Screening Kits. It also develops protein engineering and biocatalyst platforms such as Codeevolver, Ketoreductases, Transminases, Imine reductases etc. The company generates majority of its revenues from research and development activities such as license, technology, access and exclusivity fees, research service fees etc.

Ratios

Current vs industry vs history
PB Ratio 19.82
PB Ratio ranked lower than
88.36% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
CDXS: 19.82
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.84, Med: 3.96, Max: 45.13
Current: 19.82
0.84
45.13
PS Ratio 16.19
PS Ratio ranked lower than
51.38% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
CDXS: 16.19
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.27, Med: 3.1, Max: 18.9
Current: 16.19
0.27
18.9
EV-to-EBIT -87.28
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
CDXS: -87.28
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -124.3, Med: -11.6, Max: -0.4
Current: -87.28
-124.3
-0.4
EV-to-EBITDA -104.90
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
CDXS: -104.9
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -644.8, Med: -14.5, Max: 439.2
Current: -104.9
-644.8
439.2
EV-to-Revenue 16.59
EV-to-Revenue ranked higher than
52.27% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
CDXS: 16.59
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 0.2, Med: 2.7, Max: 18.7
Current: 16.59
0.2
18.7
Current Ratio 3.42
Current Ratio ranked lower than
53.82% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
CDXS: 3.42
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.14, Med: 2.57, Max: 4.04
Current: 3.42
1.14
4.04
Quick Ratio 3.38
Quick Ratio ranked lower than
51.58% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
CDXS: 3.38
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.07, Med: 2.46, Max: 3.98
Current: 3.38
1.07
3.98
Days Inventory 23.81
Days Inventory ranked higher than
83.58% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
CDXS: 23.81
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 23.5, Med: 34.73, Max: 66.14
Current: 23.81
23.5
66.14
Days Sales Outstanding 74.04
Days Sales Outstanding ranked higher than
53.74% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
CDXS: 74.04
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 31.19, Med: 54, Max: 83.52
Current: 74.04
31.19
83.52
Days Payable 60.35
Days Payable ranked higher than
55.97% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
CDXS: 60.35
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 43.52, Med: 109.73, Max: 218.83
Current: 60.35
43.52
218.83

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -9.00
3-Year Share Buyback Rate ranked higher than
70.48% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
CDXS: -9
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -143.1, Med: -5.1, Max: 1.1
Current: -9
-143.1
1.1

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 21.06
Price-to-Tangible-Book ranked lower than
83.78% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
CDXS: 21.06
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 1.34, Med: 6.03, Max: 45.45
Current: 21.06
1.34
45.45
Price-to-Median-PS-Value 5.22
Price-to-Median-PS-Value ranked lower than
92.33% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
CDXS: 5.22
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.1, Med: 0.95, Max: 5.72
Current: 5.22
0.1
5.72
Earnings Yield (Joel Greenblatt) % -1.15
Earnings Yield (Greenblatt) ranked higher than
67.72% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
CDXS: -1.15
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -244.6, Med: -8.6, Max: -0.8
Current: -1.15
-244.6
-0.8

More Statistics

Revenue (TTM) (Mil) $ 62.14
EPS (TTM) $ -0.21
Beta 1.11
Volatility % 58.22
52-Week Range $ 12.85 - 23.05
Shares Outstanding (Mil) 57.59

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA N
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N